Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297708 | 0.82 | ESR2 (0.46) | MMP2 | |
| SCHEMBL10452224 | 0.81 | PTGS2 (0.46) | ENPP2 | |
| SCHEMBL5663700 | 0.79 | PTGS2 (0.47) | — | |
| SCHEMBL6446069 | 0.78 | MMP2 (0.55) | MMP2MMP12 | |
| SCHEMBL20183917 | 0.78 | LMNA (0.56) | — | |
| SCHEMBL10753670 | 0.77 | LMNA (0.50) | MMP2MMP12 | |
| SCHEMBL20183913 | 0.76 | MMP13 (0.50) | MMP2 | |
| SCHEMBL18897536 | 0.76 | MMP2 (0.43) | MMP2MMP12 | |
| SCHEMBL2177479 | 0.75 | ENPP2 (0.48) | ENPP2 | |
| SCHEMBL6789086 | 0.75 | MMP2 (0.40) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4973750-A | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1990-11-27 | — | — | US | claimed |
| WO-2011080755-A1 | FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| US-7094789-B2 | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1541559-A1 | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| US-4973750-A | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1990-11-27 | — | — | US | disclosed |
| EP-0200739-B1 | PREPARATION OF (THREO)-1-ARYL-2-ACYLAMIDO-3-FLUORO-1-PROPANOLS | SCHERING CORPORATION (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4677214-A | Intermediates for preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0200739-A1 | PREPARATION OF (THREO)-1-ARYL-2-ACYLAMIDO-3-FLUORO-1-PROPANOLS. | SCHERING CORP (US) | 1986-11-12 | — | — | EP | disclosed |
| US-4582918-A | Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols | SCHERING CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| WO-1986001799-A1 | PREPARATION OF (THREO)-1-ARYL-2-ACYLAMIDO-3-FLUORO-1-PROPANOLS | SCHERING CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | MYLK, MYLK2, MYL12A | ENPP2 2381/4885MMP2 3448/4885MMP12 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.